Business Context and Reporting Period
The provided filing identifies the registrant as Enochian Biosciences Inc., not Lunai Bioworks Inc. It is an unaudited Form 10-Q for the quarter and six months ended December 31, 2021, representing the second quarter of the fiscal year ending June 30, 2022.
Enochian is a preclinical biotechnology company developing gene, cell, immune and other therapies targeting HIV, hepatitis B, influenza, coronavirus infections and cancer. The company has never generated revenue and expects to remain pre-revenue until product approvals and commercialization.
Key Financial Metrics
| Metric | Three Months Ended December 31, 2021 | Six Months Ended December 31, 2021 | Prior Comparable Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $6.33 million | $13.84 million | $3.31 million and $6.16 million, respectively |
| Loss from operations | $(6.33) million | $(13.84) million | $(3.31) million and $(6.16) million, respectively |
| Net loss | $(6.58) million | $(16.99) million | $(2.93) million and $(5.33) million, respectively |
| Basic and diluted loss per share | $(0.13) | $(0.33) | $(0.06) and $(0.11), respectively |
| Cash used in operating activities | Not separately disclosed | $(9.90) million | $(5.25) million |
Six-month operating expenses increased 124%, driven primarily by higher general and administrative expense and research and development expense. Stock-based compensation was $4.77 million for the six months, compared with $0.69 million in the prior-year period.
At December 31, 2021, cash was $13.71 million, compared with $20.66 million at June 30, 2021. Working capital was $8.42 million, compared with $19.01 million at June 30, 2021. Total assets were $183.14 million and total liabilities were $17.52 million.
Debt and debt-like obligations included $4.73 million of current notes payable, $1.20 million of convertible notes due February 2023, $0.67 million of premium-finance obligations, operating lease liabilities totaling approximately $1.39 million, and a $9.03 million contingent consideration liability.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased by $11.67 million, or approximately 219%, to $16.99 million.
- Six-month general and administrative expense increased 132% to $8.62 million, primarily because of higher stock-based compensation, officer compensation, salaries, laboratory and recruiting costs.
- Six-month research and development expense increased 116% to $5.15 million. Increases included a $1.50 million HBV milestone payment, $0.60 million related to ENOB-HV-21, and higher CDMO and CRO costs.
- The fair value adjustment for contingent consideration changed from $0.92 million of income in the prior-year six-month period to $2.99 million of expense, increasing the liability to $9.03 million.
- Financing activities provided $2.95 million, including $3.05 million from the Lincoln Park Capital equity purchase agreement and $0.13 million from warrant exercises. The company issued 413,606 common shares during the six-month period, increasing shares outstanding to 52,633,267.
- The company’s indefinite-lived license asset and goodwill remained recorded at $154.82 million and $11.64 million, respectively. Management reported no impairment as of December 31, 2021.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing liquidity and committed funding were believed sufficient for the next twelve months, but additional capital may be needed for equipment, personnel, research and development, IND preparation, continuing license programs and potential acquisitions. Future financing may consist of equity or debt and may not be available on acceptable terms.
Management identified potential IND-related advancement for ENOB-CV-01, ENOB-HB-01, ENOB-HV-01 and ENOB-HV-21. The filing discussed potential 2022 milestones, including an HBV IND submission toward the end of 2022 and possible clinical enrollment in late 2022 or 2023; these are forward-looking expectations, not assurances.
COVID-19 had not materially affected operations as of the filing date, but it had delayed experiments and increased animal-study costs. Further restrictions, supply or staffing limitations, research delays, regulatory delays and capital-market disruption could adversely affect development timelines and liquidity.
Related-party payments to G-Tech and affiliated entities totaled $3.54 million for the six months, including HIV consulting, HBV license and development-license costs. The company also disclosed a 3% royalty on potential net sales under the coronavirus and influenza development license.
The company reported no material pending legal proceedings and no material changes to the risk factors in its fiscal 2021 Form 10-K. However, disclosure controls were not effective because the company lacked sufficient accounting personnel to segregate approval, payment, recording and reconciliation duties. Management identified this as a material weakness and expected the deficiency to continue until sufficient capital was available to hire appropriate personnel.
Important Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing is for Enochian Biosciences Inc. and trades under ENOB, despite the request identifying Lunai Bioworks Inc.
- Verify cash runway assumptions against the $9.90 million six-month operating cash burn, $13.71 million cash balance and expected additional development expenditures.
- Review the terms, maturity and repayment requirements of the $5.00 million unsecured note, $1.20 million convertible notes and premium-finance agreement.
- Assess dilution from the Lincoln Park equity facility, outstanding options, warrants, contingent shares and additional financing needs.
- Evaluate the valuation sensitivity of the $9.03 million Level 3 contingent consideration liability and the $166.46 million of indefinite-lived intangible assets and goodwill.
- Review related-party transactions and license commitments, including the HBV milestone payment, coronavirus and influenza license funding and potential future milestone obligations.
- Monitor remediation of the material weakness in internal control over financial reporting.
- Independently verify the stated preclinical, regulatory and clinical development timelines, as the filing provides no assurance that products will obtain regulatory approval or generate revenue.